Applied Therapeutics Inc 2025年季度报告

(Mark One)☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the quarterly period endedMarch 31,2025OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the transition period from ______________ to ______________Commission File Number:001-38898 Applied Therapeutics, Inc.(Exact Name of Registrant as Specified in its Charter) 81-3405262(I.R.S. EmployerIdentification No.) Delaware(State or other jurisdiction ofincorporation or organization) 545 Fifth Avenue,Suite 1400New York,New York10017(Address of principal executive offices, zip code) (212)220-9226(Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirementsfor the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 ofRegulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or anemerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” inRule 12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revisedfinancial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒As of May 12, 2025, the registrant had141,575,526shares of common stock, $0.0001 par value per share, outstanding. Table of Contents PageSpecial Note Regarding Forward-Looking Statements2PART I.FINANCIAL INFORMATIONItem 1.Financial Statements (Unaudited)4Condensed Balance Sheets4Condensed Statements of Operations5Condensed Statements of Stockholders’ Equity/(Deficit)6Condensed Statements of Cash Flows8Notes to Condensed Financial Statements (Unaudited)9Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations27Item 3.Quantitative and Qualitative Disclosures About Market Risk38Item 4.Controls and Procedures39PART II.OTHER INFORMATIONItem 1.Legal Proceedings41Item 1A.Risk Factors41Item 2.Unregistered Sales of Equity Securities and Use of Proceeds93Item 3.Defaults Upon Senior Securities94Item 4.Mine Safety Disclosures94Item 5.Other Information94Item 6.Exhibits95Signatures96 We own various U.S. federal trademarks, including our company name and logo, that we use in connection with theoperation of our business. This Quarterly Report on Form 10-Q includes our trademarks and trade names which are protected underapplicable intellectual property laws and are our property. This Quarterly Report on Form 10-Q also contains trademarks, tradenames and service marks of other companies, which are the property of their respective owners. Solely for convenience,trademarks, trade names and service marks referred to in this Quarterly Report on Form 10-Q may appear without the ®, ™ or SMsymbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent permitted underapplicable law, our rights or the right of the applicable licensor to these trademarks, trade names and service marks. We do notintend our use or display of other parties’ trademarks, trade names or service marks to imply, and such use or display should not beconstrued to imply, a relationship with, or endorsement or sponsorship of us by, these other parties. From time to time, we may use our website and our X (formerly known as Twitter) account at @Applied_Tx to distributematerial information about us and for complying with our disclosure obligations under Regulation FD. Our financial and othermaterial information is routinely posted to and accessible on the Investors section of our website, available atwww.appliedtherapeutics.com. Investors are encouraged to review the Investors & Media section of our website because we maypost material information on that site that is not otherwise disseminated by us. Information that is contained in and can be accessedthrough our website and our X posts are not incorporated into, and does not form a part of, this Quarterly Report on Form 10-Q. SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q may c